
Please type a plus sign (+) inside this box -> +



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM LEMBS e used for all correspondence after initial filing)			Application Number	09/155,739
			Filing Date	September 11, 1998
			First Named Inventor	Yednock, Ted A.
			Group Art Unit	1642
		Examiner Name	Mrs. Wallace	
Total Number of Pages in This Submission 1			Attorney Docket Number	015270001430
		ENCLO	DSURES (check all that apply)	TH 9
Fee Transmittal	Form		ment Papers Application)	After Allowance Communication of Group
Fee Attached		☐ Drawin	g(s)	Appeal Communication to Appeals and Interference
Amendment / Response		Licensi	ng-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final			n Routing Slip (PTO/SB/69)	Proprietary Information
Affidavits/declaration(s)		Petition to Convert to a Provisional Application		Status Letter
Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address		Other Enclosure(s) (please identify below):
Express Abandonment Request		☐ Terminal Disclaimer		34 References
		Reques	st for Refund	Return Postcard
Information Disclosure Statement		CD, Nu	mber of CD(s)	
Certified Copy of Priority Document(s)		Remar	Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	
Response to Missing Parts/ Incomplete Application				
Response to Missing Parts under 37 CFR 1.52 or 1.53				
	SIGNA	TURE OF A	APPLICANT, ATTORNEY, O	R AGENT
Firm	Townsend and Tov			
Individual name Andrew T. Serafini, Ph.D.		Reg No	. 41,303	
Signature Andrew Est				
Date	October 9, 2001	1		
		CEF	RTIFICATE OF MAILING	
		being depos		al Service with sufficient postage as first on, D.C. 20231 on this date: October 9, 2001
Typed or printed nam	ne Kathy Johnsk	on ,		
Signature	Ketho	1 5	/	Date October 9, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3175607 v1

I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope addressed to

Assistant Commissioner for Patents Washington, D.C. 20231

on Notaber 9,2001

TOWNSEND and TOWNSEND and CREW LLP

<u>PATENT</u>

Attorney Docket No.: 015270-001430US

Client Reference No.: 120-US-CIP1

RECEIVED TECHCENTER TOOLOGO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 1 8 2001

In re application of:

Mary M. Bendig et al.

Application No.: 09/155,739

Filed: September 11, 1998

For: THERAPEUTIC USES OF

HUMANIZED ANTIBODIES AGAINST

ALPHA-4 INTEGRIN

Examiner:

Gambel, P.

Art Unic

1644

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Elan Pharmaceuticals Application No.: 09/155,739

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of a first Office Action. This Office Action was an Election/Restriction Requirement and therefore is not an action on the merits.

Therefore, Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Andrew T. Serafini

Reg. No. 41,303

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

ATS:rnh

PA 3173153 v2